Angels for Change and Every Cure announced a collaboration aimed at strengthening patient access to repurposed medicines and advancing a more resilient, patient-centered healthcare system.

Angels for Change and Every Cure share a commitment to ensuring patients have access to the treatments they need– whether that means discovering and advancing new uses for existing medicines or ensuring those medicines are available when patients need them. By combining expertise in drug shortages, supply chain resilience, and drug repurposing, the partnership will support shared efforts to expand access to lifesaving therapies. Particularly for generic essential medicines that form the backbone of healthcare. 

The 2025 USP Drug Shortages Report has been released, and it highlights a troubling trend: discontinuations of essential, life-saving medicines continue to rise.

In 2025, drug product discontinuations increased by 60%, reaching the highest annual total in 5 years. Drug shortages are often driven by single points of failure; medicines that are manufactured at only one facility or place in the world. When products are discontinued, the market becomes even more concentrated, leaving patients with fewer treatment options and fewer backup sources when disruptions occur.

The 2025 Angels for Change Impact Report: 5 Years of Change Edition is here. This special mile5tone edition reflects on the progress, partnerships, and patient-centered solutions that shaped our journey and defined our impact in 2025.

Angels for Change announced a major milestone in Project PROTECT, its national initiative focused on building ready-to-activate domestic manufacturing capacity for essential medicines vulnerable to shortages. Through a new partnership with Medivant Healthcare, 10% Calcium Chloride Injection is now protected with onshore manufacturing readiness in the U.S., helping safeguard patient access during future supply disruptions. The collaboration strengthens domestic supply chain resilience for this critical medication used in emergency medicine, cardiac resuscitation, and intensive care.

In a recent interview with Healthcare Brew, Laura Bray discussed how the Iran war could create new vulnerabilities across the global pharmaceutical supply chain, adding pressure to a system already struggling with ongoing drug shortages.